Indivior PLC

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.

Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered second SUBLOCADE injection a week later vs. standard 28 days, enabling patients to achieve and maintain target medication levels more quickly.

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Indivior PLC (LSE:INDV) said it remains open-minded about proposals from Oaktree Capital Management LP aimed at enhancing shareholder value, despite the activist investor's call for a board overhaul. The specialty pharma group, which makes opioid withdrawal drugs, said it had been actively engaging with Oaktree in recent weeks and reiterated its commitment to its current strategy while prioritising the best interests of all shareholders.

Indivior says it remains open-minded on activist investor Oaktree's proposals

RICHMOND, Va. , Nov. 7, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ("Oaktree") to the Board of Indivior.

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

RICHMOND, Va., Oct. 30, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV), in recognizing Substance Abuse Prevention Month, provides an update on key findings from the last year that demonstrate the importance of access to medications for the treatment of opioid use disorder (MOUD) and the effectiveness and safety of SUBLOCADE® in the treatment of OUD. These data add to the growing body of evidence that SUBLOCADE can improve outcomes, such as abstinence, retention, and recovery in persons with OUD.

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Indivior PLC (NASDAQ:INDV ) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Jason Thompson - Head, IR Mark Crossley - CEO Christian Heidbreder - Chief Scientific Officer Ryan Preblick - CFO Conference Call Participants David Amsellem - Piper Sandler Chase Knickerbocker - Craig-Hallum Paul Cudden - Deutsche Numis Christian Glennie - Stifel Operator Good day and thank you for standing by. Welcome to the Indivior PLC Third Quarter 2024 Conference Call.

Indivior PLC (INDV) Q3 2024 Earnings Call Transcript

Indivior PLC (INDV) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.34 per share a year ago.

Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates

Indivior PLC (LSE:INDV)'s share price jumped 11% after the company reaffirmed its full-year outlook despite recent challenges, including increased competition for its opioid addiction treatment, Sublocade. In its third-quarter results, Indivior posted a 13% revenue increase to $307 million, with Sublocade sales rising 14% to $191 million.

Indivior shares motor 11% after reassuring update; brokers positive

Indivior PLC (LSE:INDV) has maintained its full-year outlook, which is in part reassuring and slightly odd given the profit warning it issued two weeks ago effectively reset expectations. In its third-quarter results, the company cited short-term 'headwinds' but spoke of the longer-term picture as it attempted to allay investors' anxieties over increased competition from the newly launched Brixadi for its opioid addiction treatment, Sublocade.

Indivior moves to shore up confidence in Sublocade

SLOUGH, United Kingdom and RICHMOND, Va. , Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024.

Indivior Announces Q3 2024 Financial Results

Indivior PLC (LSE:INDV) received a sharp downgrade from investment bank Stifel, cutting its price target from 2,100p to 1,400p, following the company's second profit warning of 2024. Stifel cites rising competition from rival drug Brixadi as a key reason for lowering estimates and slashing earnings forecasts by more than 20%.

Indivior price target slashed after second profit warning of the year

Indivior is a $970m small-cap facing to transitory headwinds resulting in extremely negative sentiment and fascinatingly low valuation. Due to the extreme mis-pricing I argue Indivior offers investors great risk/reward asymmetry with upside potential of 104% based on today's share price of $7.46. Temporary headwinds like Medicaid disenrollments, market share loses affecting Sublocade growth and ongoing antitrust litigations are priced in at a current forward EV/EBITDA of 2.3x.

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

Indivior PLC (LSE:INDV) shares dropped over 16% after the drug company warned that sales of its Sublocade long-lasting opioid addiction treatment were hit by a rise in rival generic versions.  Management of the group now sees lower than expected revenue from Sublocade in the third quarter and full year from a combination of faster initial adoption of a competitor's rival long-acting injectable treatment, as well as other factors.

Indivior plunges on profit warning as rival anti-opioid product sells faster than expected

British drugmaker Indivior on Thursday cut its 2024 net revenue forecast for the second time in three months, citing lower than expected revenues from its Sublocade treatment for opioid use disorder, sending shares 15% lower.

British drugmaker Indivior cuts 2024 revenue forecast, shares fall

Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va.

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a single transmucosal buprenorphine dose; both of which address significant patient and healthcare provider unmet needs. RICHMOND, Va.

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=106508&wire=1 or contact Joseph E. Levi, Esq.

Investors in Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights – INDV

NEW YORK , Oct. 1, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Indivior PLC ("Indivior" or the "Company") (NASDAQ: INDV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Indivior investors who were adversely affected by alleged securities fraud between February 22, 2024 and July 8, 2024.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Indivior PLC(INDV) Shareholders

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=106403&wire=1 or contact Joseph E. Levi, Esq.

Investors in Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Indivior PLC ("Indivior" or the "Company") (NASDAQ:INDV) and certain officers. The class action, filed in the United States District Court for the Eastern District of Virginia (Richmond Division), and docketed under 24-cv- 00554, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Indivior securities between February 22, 2024 and July 8, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officers.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Indivior PLC of Class Action Lawsuit and Upcoming Deadlines - INDV

LOS ANGELES--(BUSINESS WIRE)--INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm.

INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=106338&wire=1 or contact Joseph E. Levi, Esq.

Indivior PLC Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV

NEW YORK CITY, NY / ACCESSWIRE / October 1, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Indivior PLC ("Indivior" or "the Company") (NASDAQ:INDV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Indivior securities between February 22, 2024, and July 8, 2024, inclusive (the "Class Period").

FINAL INDV DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Indivior PLC Investors to Join the Class Action Lawsuit!

Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses

Indivior PLC Investors: Please contact the Portnoy Law Firm to recover your losses. October 1, 2024 Deadline to file Lead Plaintiff Motion

NEW YORK, NY / ACCESSWIRE / September 30, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=106253&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior Lawsuit – INDV

NEW YORK, NY / ACCESSWIRE / September 30, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=106247&wire=1 or contact Joseph E. Levi, Esq.

News for Indivior PLC Stock (INDV)